Do You See Adult Patients Like This in Your Practice?

Adequately treated with INVEGA SUSTENNA® for at least 4 months, with the last 2 doses being the same:

  • Achieved consistent schizophrenia symptom control
  • Demonstrated established tolerability
  • Consistently receiving monthly injections of INVEGA SUSTENNA®
  • Progressed to stage in treatment journey where he/she is ready to pursue long-term treatment goals with less frequent dosing
Are you offering your adult patients with schizophrenia the option of progressing to the longest dosing interval available?
patient-type

New Clinical Guidance Supports Earlier Use of LAIs in Adults With Schizophrenia3

national-council

The National Council for Behavioral Health supports the safe and effective use of LAIs by encouraging mental healthcare professionals to utilize LAIs as an earlier treatment option.

LAI=Long-Acting Injectable 

INVEGA TRINZA® Has Demonstrated Longer Time to Relapse vs Placebo1,4

time-to-relapse-efficacy

A randomized, double-blind, placebo-controlled, long-term maintenance study compared 3-month INVEGA TRINZA® with placebo1,4

total-panss-efficacy

INVEGA TRINZA® provided significant symptom improvement in PANSS total scores

PANSS=Positive and Negative Syndrome Scale

With INVEGA TRINZA® You Can be Confident Adult Patients Receive up to 3 Months of Medication1,2

plasma-concetrations

Due to the difference in median pharmacokinetic profiles between the 2 products (INVEGA TRINZA® and INVEGA SUSTENNA®), caution should be exercised when making a direct comparison of their pharmacokinetic properties.2

The Formulation of INVEGA TRINZA® Allows for Gradual Release of the Medicine1

INVEGA TRINZA® 3-Month Formulation2

formulation

A Retrospective Real-world Claims Analysis Showed Most Schizophrenia Patients Returned for Treatment

After treatment with INVEGA SUSTENNA® for at least 4 months, the majority of adult schizophrenia patients who were transitioned to INVEGA TRINZA® per label* returned for treatment

real-world-2

Based on a retrospective cohort analysis of pharmacy and medical claims data, of adult patients with schizophrenia (n=1603), from the Symphony Health Solutions (SHS) database from May 2014 to September 2016. First data on patient claims for INVEGA TRINZA® were from July 2015.

  • Claims databases such as SHS are subject to billing inaccuracies and missing data
  • Data are real-world usage patterns only; there are no associated clinical/economic outcomes
  • Findings are based on medication dispensed date, not administration of medication

Patient Claims Data

SHS, a robust open-source database, captures prescription transactions for roughly 75% of the US population annually (approximately 260 million patients). The database does not capture services received outside of the SHS network.6

References: 1. INVEGA TRINZA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2019. 2. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ. 3. National Council for Behavioral Health. Guide to Long-acting Medications for Providers and Organizations. https://www.thenationalcouncil.org/topics/long-acting-medications/. Published June 5, 2019. Accessed June 5, 2019. 4. Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830-839. Supplemental data available at: http://archpsyc.jamanetwork.com/article.aspx?articleid=2211343#tab12. Accessed November 8, 2019. 5. Joshi K, Lafeuille MH, Brown B, et al. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-month paliperidone palmitate in the real-world setting. Curr Med Res Opin. 2017;33:10: 1763-1772. 6. Data on file. Symphony Health Solutions. Janssen Pharmaceuticals, Inc., Titusville, NJ.